Activation of PI3K-AKT/MAPK signaling promotes PCa cell proliferation and survival, hence combining PI3K-AKT/MAPK inhibitors with anti-androgen therapy were found to be promising in clinical trials [58,59]. The gene discussed is AKT1; the disease is posterior cortical atrophy.